Quantcast
Last updated on April 16, 2014 at 11:32 EDT

Latest Trastuzumab Stories

2011-07-11 19:51:22

Combination therapy benefits more than a third of women in study Adding Afinitor® to Herceptin®, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology. The Phase I/II study demonstrated that a combination of the...

2011-06-28 13:13:52

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)." In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the different subtypes respond in cultured cells and animal tumor models. Knowing the...

2011-06-14 17:56:00

TUCSON, Ariz., June 14, 2011 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced today that the FDA approved the INFORM HER2 Dual ISH DNA Probe cocktail assay (HER2 Dual ISH) for commercialization in the United States. This is the first fully automated assay approved by the FDA for determination of HER2 gene status in breast cancer as an aid in the assessment of patients considered for treatment with Herceptin (trastuzumab). For breast cancer...

2011-06-14 11:15:00

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor...

2011-06-09 06:00:00

INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase. The revision to the earlier guidance of $128 million is due to a mathematical error. The forecasted growth is primarily driven by increased first quarter 2011 sales...

2011-06-07 08:15:00

SAN DIEGO, June 7, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM). Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago. On June 6, scientists from bioTheranostics and the Institut...

2011-06-06 12:52:41

ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators. The study, which looked at tumors from 1,802 patients enrolled in the NCCTG N9831 clinical trial, found that patients with HER2-positive breast cancer and had either a loss of PTEN functioning or normal PTEN activity...

2011-06-03 13:30:48

Results from Phase 2 study at University Hospitals Case Medical Center, UCSF and Columbia In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate. Patients in the study, conducted at University Hospitals Case Medical Center, University of...

2011-06-01 06:00:00

INCLINE VILLAGE, Nev., June 1, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2011, of approximately $128 million, as compared with actual results of $120 million for the second quarter of 2010, an expected seven percent year-over-year increase. The forecasted growth is primarily driven by increased first quarter 2011 sales of Herceptin®, Lucentis® and...

2011-05-19 12:59:00

NEW YORK, May 19, 2011 /PRNewswire/ -- NexGenix Pharmaceuticals Inc., a privately-held company developing treatments for cancer, neurodegenerative diseases, and orphan neurogenetic disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent for a platform of Hsp90 inhibitors based on derivatives of the naturally occurring pochonin family, Pochonia chlamydospora. The platform of fully synthetic small molecules...